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Abstract
Objective: To investigate the damage to the retinal nerve fiber layer as part of the anterior visual pathway as well as an
impairment of the neuronal and axonal integrity in the visual cortex as part of the posterior visual pathway with
complementary neuroimaging techniques, and to correlate our results to patients’ clinical symptoms concerning the visual
pathway.
Design, Subjects and Methods: Survey of 86 patients with relapsing-remitting multiple sclerosis that were subjected to
retinal nerve fiber layer thickness (RNFLT) measurement by optical coherence tomography, to a routine MRI scan including
the calculation of the brain parenchymal fraction (BPF), and to magnetic resonance spectroscopy at 3 tesla, quantifying N-
acetyl aspartate (NAA) concentrations in the visual cortex and normal-appearing white matter.
Results: RNFLT correlated significantly with BPF and visual cortex NAA, but not with normal-appearing white matter NAA.
This was connected with the patients’ history of a previous optic neuritis. In a combined model, both BPF and visual cortex
NAA were independently associated with RNFLT.
Conclusions: Our data suggest the existence of functional pathway-specific damage patterns exceeding global
neurodegeneration. They suggest a strong interrelationship between damage to the anterior and the posterior visual
pathway.
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Introduction
Already in the 19
th century, Charcot reported a regular
occurrence of neuronal and axonal degeneration beyond demy-
elination in multiple sclerosis (MS) [1]. Unfortunately, these
findings were neglected by the research community for a long
time, and consequently MS was seen as a primarily demyelinating
condition, with relative preservation of axons and neurons [2].
However, within the past two decades, Charcot’s initial descrip-
tions enjoyed a revival, mainly by the advent of advanced
microscopic imaging techniques, such as the combination of
fluorescent immunocytochemistry with confocal microscopy.
Several groups could show that independently of the demyelin-
ation process neuronal and axonal breakdown contribute to
central nervous system (CNS) tissue damage and the resulting
functional deficits in different stages in the course of MS [3]. It is
now well accepted that MS is not only a demyelinating CNS
disease but has also a considerable neurodegenerative component
[4]. In the light of these findings, therapeutic strategies that
specifically address the neurodegenerative component of MS are
in the focus of the research. Also in neuroimaging, there is a shift
of research interest from a mere depiction of the inflammatory
aspects of the disease such as T2- and contrast enhancing lesion
load which only correlate modestly with the clinical disease course
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paradox[5]) to improved techniques to quantify and monitor
neurodegeneration. Brain atrophy is considered to represent at
least partially axonal and neuronal loss in MS[6] and shows a
strong association with some clinical disease-related measures. It
can be quantified by various techniques, e.g. the calculation of the
so-called brain parenchymal fraction (BPF) [7–8] but its
appropriateness as primary endpoint in clinical trials on
neuroprotective therapies still remains to be proven.
In recent years, optical coherence tomography (OCT) evolved
as a valuable non-invasive diagnostic tool to image unmyelinated
retinal CNS axons and thus to depict MS-related neurodegener-
ation (reviewed in [9],[10]). Based on the concept that ongoing
diffuse neurodegeneration in the brain will also affect the retinal
CNS axons, different groups reported reduced retinal nerve fiber
layer thickness (RNFLT) in MS patients versus healthy con-
trols[11–12] and could show that RNFLT correlates well with
brain atrophy and physical and cognitive disability[13–16].
Proton magnetic resonance spectroscopy (
1H-MRS) emerged as
technique to quantify MS-related neuronal and axonal damage by
measuring the brain N-acetyl-aspartate (NAA) concentration, a
presumed marker of axonal and neuronal integrity (reviewed in
[17]). In line with the change of paradigm on MS pathology,
1H-
MRS provides evidence for metabolic alterations in normal
appearing white matter in MS [18–19].
Against the background of these findings, we were interested
whether changes in RNFLT indicating alterations of the anterior
visual pathway are linked to impaired neuronal and axonal
integrity in the visual cortex as part of the posterior visual
pathway. We performed a cross-sectional study to investigate the
association of RNFLT with NAA of the normal appearing white
matter and the visual cortex as measured by
1H-MRS, and with
BPF as a parameter of global brain tissue loss.
Methods
Participants
Using an exploratory cross-sectional study design, relapsing-
remitting multiple sclerosis (RRMS) patients fulfilling the current
panel criteria[20] were prospectively recruited between September
2007 and February 2009. The study was approved by the ethics
committee of Charite ´ Universita ¨tsmedizin Berlin, Germany and
all participants gave informed written consent according to the
1964 Declaration of Helsinki. Patients with MS met the following
criteria: age 18-55 years, stable immunomodulatory therapy with
glatiramer acetate for at least six months prior to inclusion, EDSS
between 0 and 6.5, no acute relapse and no systemic steroid
treatment within 30 days prior to enrolment. Patients with
ophthalmologic disorders or medical conditions with impact on
retinal nerve fiber layer (e.g. diabetes, glaucoma) were not
included. The patients included in this study are the sub-group
of patients recruited for an ongoing clinical drug trial with
glatiramer acetate as required co-medication, from whom baseline
data of both 1.5T MR imaging and 3T magnetic resonance
spectroscopy were available. Demographic data are summarized
in Table 1.
Clinical and visual assessment
Medical history, particularly with respect to visual symptoms,
was taken from all study participants. Based on the documented
previous history of optic neuritis (ON), we defined three subgroups
of patients – patients with no, unilateral and bilateral optic
neuritis. None of the study subjects had suffered from acute optic
neuritis within the last 6 months before recruitment to the study.
All participants underwent a complete ophthalmologic examina-
tion, including non-contact tonometry, visual acuity testing by
using Snellen charts, Nieden charts and functional acuity contrast
testing, spheric refractive error testing and cylindric refractive
error testing. Patients who showed a non-MS related eye
pathology were excluded from OCT measurements. Neurological
disability in MS patients was assessed by the expanded disability
status scale (EDSS) [21].
Optical coherence tomography
RNFLT was measured with a Stratus 3000 OCT (Carl Zeiss
Meditec, Dublin, California) using the ‘‘fast RNFL 3.4’’ protocol
(software version 4.0). Three 3.4 mm diameter circular scans were
acquired over 1.92 seconds. A good quality image was defined as
an image with generalised signal distribution, a reflectance signal
from either RNFL or retinal pigment epithelium strong enough to
identify either layer, no missing parts caused by eye movements,
and a signal strength of $8 of 10 [22]. The segmentation line
defining the upper and lower border of the RNFL was required to
be on the internal limiting membrane and lower border of the
Table 1. Summary of demographic data, mean RNFLT, mean BPF, mean normal-appearing white matter (NAWM) NAA
concentrations, mean visual cortex (VC) NAA concentrations.
All Patients NON/NON Patients NON/ON Patients ON/ON Patients
Patients (%) 86 (100) 53 (61.6) 20 (23.3) 13 (15.1)
Age, mean (range), y 41 (21–60) 40 (21–60) 41 (24–60) 41 (32–56)
Disease Duration,
mean (range), m
71 (4–271) 65 (4–271) 92 (11–193) 68 (7–147)
EDSS, median (range) 2.0 (0.0–6.0) 2.0 (0.0–6.0) 2.0 (1.0–4.5) 2.5 (0–4.5)
Min. RNFLT Average,
mean (SD; range), mm
91.3 (15; 46–123) 97.3 (10; 74–123) 84.6 (17.3;46–111) 75 (14.2; 56–104)
BPF, mean (SD; range) 0.851 (0.031; 0.77–0.918) 0.855 (0.032; 0.77–0.918) 0.849 (0.03; 0.791–0.913) 0.838 (0.026; 0.789–0.872)
NAWM NAA, mean
(SD; range), mmol/l
13.079 (1.354; 7.652–15.807) 13.192 (1.25; 10.909–15.807) 12.994 (1.714; 7.652–15.65) 12.746 (1.212; 11.026–15.344)
VC NAA, mean
(SD; range), mmol/l
13.471 (1.017; 11.176–16.086) 13.601 (1.023; 11.176–16.086) 13.43 (0.996; 11.57–14.783) 13.002 (0.948; 11.401–14.651)
(NON/NON – no previous optic neuritis, NON/ON – previous unilateral optic neuritis, ON/ON - previous bilateral optic neuritis).
doi:10.1371/journal.pone.0018019.t001
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The OCT A-scan data were digitally exported in a blinded
fashion.
Magnetic resonance imaging and brain parenchymal
fraction calculation
MRI measurements were performed on a 1.5 tesla scanner
(Avanto, Siemens Medical Systems, Erlangen, Germany). A three-
dimensional T1-weighted image (MPRAGE) was acquired
according to the following protocol: TR 1.9 ms, TE 3.09 ms, TI
1.1 ms, flip angle 15u, matrix size 1 mm
3. Brain tissue volume,
normalized for subject head size, was estimated applying
SIENAX[23–24],part of FSL [25]. SIENAX starts by extracting
brain and skull images from the single whole-head input data [26].
The brain image is then affine-registered to MNI152 space (using
the skull image to determine the registration scaling) [27–28] in
order to obtain the volumetric scaling factor to be used as
normalization for head size. Next, tissue-type segmentation with
partial volume estimation is carried out in order to calculate total
volume of brain tissue [29].
MR spectroscopy
MR measurements were carried out on a 3 tesla scanner
(MEDSPEC 30/100, Bruker Biospin, Ettlingen, Germany). T1-
weighted images were acquired using MDEFT (modified driven
equilibrium Fourier transform, with TE=3.8 ms, TR=20.53 ms;
128 contiguous slices, 1.5 mm thick; 1-mm in-plane (x–y)
resolution). After localized shimming, magnetic resonance spectra
were recorded from two voxels located in left and right normal
appearing periventricular white matter (26262c m
3), and a voxel
centered on the visual cortex (36262c m
3) (Fig. 1). The PRESS
(point resolved spectroscopy) sequence preceded by water suppres-
sion (3 Gauss CHESS pulses of 25.6 ms duration) was used
throughout. Details of the procedure for metabolite quantification
were previously published [30]. For one metabolite spectrum eight
subspectra of 16 phase cycled scans each were recorded with
TR=3s and T E=80 ms. Before further processing, the 8
metabolite subspectra were corrected for eddy currents using
water-unsuppressed spectra (TR and TE as above), automatically
corrected for frequency and phase shifts, and added together to give
128 averages. Spectral quantification was carried out using a time
domain-frequency domain fitting procedure that involves back-
ground estimation by regularization [31]. Any residual contribu-
tions by macromolecules are accommodated in the baseline by the
fitting procedure. Mean uncertainties corresponding to Crame ´r-
Rao lower bounds with added uncertainties from the background
modelling[31] for the fitting of NAA were as small as 2.1% for the
visual cortex voxel and 2.4%for the normal-appearing white matter
voxels. The fitted NAA amplitudes were corrected for different coil
loading by an aqueous metabolite phantom used for spectrum
analysis and the individual subject’s head (principle of reciprocity),
and for transverse relaxation effects using mean T2 values measured
earlier at 3 T for normal-appearing white matter [32] and cortical
regions [30]. Longitudinal relaxation effects were neglected because
T1 was assumed to be similar in the aqueous phantom and in brain
tissue. Metabolite concentrations were corrected for cerebrospinal
fluid (CSF) in the voxels studied by using the CSF fractions obtained
by segmenting the T1-weighted images with SPM2 (www.fil.ion.ucl.
ac.uk/spm/spm2.html).
Statistical analysis
RNFLT,
1H-MRS and BPF data were analyzed for normal
distribution using skewness and kurtosis of data histograms. All
data was within +/-1.5 skewness and kurtosis. Additionally,
Shapiro-Wilk tests were performed to check for normal distribu-
tion. According to these tests, RNFLT, BPF, visual cortex NAA
were normally distributed whereas NAA in normal-appearing
white matter was not (Shapiro-Wilk test, p=0.037).
Correlation between normal-appearing white matter NAA and
visual cortex NAA and BPF was assessed using Pearson’s
correlation coefficient, counterchecked with Spearman’s correla-
tion due to the distribution of the normal-appearing white matter
NAA. Association of normal-appearing white matter and visual
cortex NAA and BPF with RNFLT was tested with Generalized
Estimating Equation Models (GEE) to adjust for inter-eye
dependencies within patients using RNFLT as the dependent
variable and BPF, visual cortex voxel NAA or normal-appearing
white matter NAA as single independent variables. Finally, a GEE
with BPF and visual cortex NAA as independents and RNFLT as
dependent variable was used to calculate the independent
association of BPF and visual cortex NAA with RNFLT (combined
model). Since GEE function in PASW 18 does not provide
standardized output for coefficients, we approached this issue in
the following way: RNFLT, BPF and visual cortex NAA were
transformed to standardized z-values and each GEE was
performed again with these z-values instead of the original values
(standardized Beta, see Table 2).
Analyses of variance were performed with BPF, visual cortex
NAA or normal-appearing white matter NAA as dependent
variable and history of ON as nominal independent factor to
identify group differences regarding BPF, visual cortex NAA and
normal-appearing white matter NAA between patients with
history of bilateral optic neuritis, patients with history of unilateral
optic neuritis and without previous optic neuritis. Differences in
age, EDSS and disease duration between these groups defined by
history of optic neuritis were assessed with Kruskal-Wallis tests,
differences in gender with Pearson’s Chi Square analysis.
All statistical tests were performed using PASW 18 (SPSS,
Chicago, IL, USA). For all calculations, statistical significance was
established at p,0.05. Data sets with partly missing data as
indicated under results were not excluded from sub-analyses. All
tests should be understood as constituting exploratory data
analysis, such that no adjustments for multiple testing were made.
Results
86 RRMS patients were recruited. Three patients were
excluded from OCT analysis due to non-MS related retinal
pathologies. All other eyes were included and were analyzable with
an RNFLT signal strength $8. Data from
1H-MRS measure-
ments were available for all patients. In five patients BPF analysis
was not performed due to insufficient image quality (e.g. motion
artifacts). Patients in the three subgroups defined by history of
optic neuritis did not differ significantly regarding age (Kruskal-
Wallis, p=0.947), disease duration (Kruskal-Wallis, p=0.172),
EDSS (Kruskal-Wallis, p=0.829) or gender (Chi-Square,
p=0.768). Clinical and demographical data including history of
optic neuritis, RNFLT, BPF and
1H-MRS are given in Table 1.
BPF correlates with RNFLT but not with NAA
concentration in visual cortex and normal-appearing
white matter
BPF correlated with RNFLT (GEE, CI95% low =0.55 mm/%,
high =2.11 mm/%, p,0.001). There was no correlation between
visual cortex NAA concentration and BPF (Pearson, p=0.161) or
normal-appearing white matter NAA concentration and BPF
(Pearson, p=0.540). Comparing the BPF in the three subgroups
Visual Cortex NAA and RNFLT in Multiple Sclerosis
PLoS ONE | www.plosone.org 3 April 2011 | Volume 6 | Issue 4 | e18019defined by history of optic neuritis there was a trend towards lower
BPF in patients with previous episodes of optic neuritis (ANOVA,
p=0.055) (Figure 2A and B). Further statistical details, including a
calculated standardized coefficient, are provided in Table 2.
RNFLT correlates with NAA concentration in the visual
cortex but not in the normal-appearing white matter
We found a correlation between RNFLT and visual cortex
NAA concentration (GEE, Confidence Interval (CI95%) low =
0.03 mm/(mmol/l), high =5.61 mm/(mmol/l), p=0.047). The
subgroups regarding history of optic neuritis differed in their visual
cortex NAA concentration, indicating that patients with previous
unilateral or bilateral optic neuritis exhibited lower NAA levels
than those without optic neuritis (ANOVA, p=0.046), (Figure 2C
and D). There was no correlation between RNFLT and NAA
concentration in the normal-appearing white matter (GEE,
CI95% low = 21.26 mm/(mmol/l), high =2.44 mm/(mmol/l),
p=0.531), nor a difference in normal-appearing white matter
NAA concentration between subgroups regarding the history of
optic neuritis (ANOVA, p=0.429) (Figure 2E and F). (Further
statistical details, including a calculated standardized coefficient,
are provided in Table 2.)
BPF and visual cortex NAA concentrations are
independently associated with average RNFLT
Using visual cortex NAA concentration and BPF as indepen-
dent variables in a multivariate GEE analysis, we found that both
BPF (CI 95% low =0.45 mm/%, high =1.96 mm/%, p=0.002)
and visual cortex NAA concentration (CI 95% low =0.10 mm/
(mmol/l), high =5.47 mm/(mmol/l), p=0.042) are independently
associated with RNFLT. Further statistical details, including a
calculated standardized coefficient, are provided in Table 2.
Figure 1.
1H-MRS voxel placement. Visual representation of typical voxel placement for MR spectroscopy. In each patient, NAA concentrations
were measured in a visual cortex voxel (VC) and two normal-appearing white matter voxels (NAWM).
doi:10.1371/journal.pone.0018019.g001
Table 2. Statistical data for GEE and combined model GEE (NAWM=normal-appearing white matter, VC=visual cortex).
Variable
Dependent
Variable B (Std. Error; 95% CI)
standardized B
(Std. Error; 95% CI) Chi-Square P value
GEE 1 VC-NAA RNFLT 2.823 (1.4238; .033–5.614) .191 (.0964; .002–.380) 3.932 .047
GEE 2 BPF RNFLT 132.907 (39.941; 54.625–211.190) .269 (.0809; .111–.428) 11.073 .001
GEE Combined model BPF RNFLT 120.448 (38.3810; 45.223–195.673) .244 (.0777; .092–.396) 9.848 .002
VC-NAA RNFLT 2.784 (1.3720; .095–5.473) .188 (.0929;.006–.370) 4.117 .042
doi:10.1371/journal.pone.0018019.t002
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This cross-sectional study is the first to investigate MS-related
axonal and neuronal damage in a large number of patients by
three different imaging modalities including OCT, brain atrophy
measurement by MRI, and
1H-MRS of the visual cortex and
normal-appearing white matter at 3 T. Our main findings are that
(i) RNFLT is correlated with NAA concentration in the visual
cortex but not in the normal-appearing white matter, (ii) visual
cortex NAA concentrations are lower in patients with previous
optic neuritis than in those without, (iii) both visual cortex NAA
and BPF are independently associated with RNFLT, and (iv) BPF
and RNFLT show a significant association.
The novel multimodal imaging approach merging OCT and
MRI and the additional application of
1H-MRS at 3 T, yielding
an improved signal-to-noise ratio compared to 1.5 T[17] enabled
us to investigate not only the relationship between brain atrophy
and RNFL reduction which had already been assessed previously
in smaller patient cohorts[13] [15] and by us in a larger patient
cohort (Do ¨rr et al., submitted), where we analyzed the association
of RNFLT and the total macular volume with global brain
atrophy, but to evaluate also the association between disease-
related damage of the anterior part (RNFLT by OCT) and that of
the retrogeniculate part of the visual pathway (NAA in the visual
cortex by
1H-MRS). Thus, our combined OCT and
1H-MRS data
may suggest an interconnection of MS-associated neurodegener-
ation in both parts of the visual pathway. The multivariate
statistical model revealed that the correlation of RNFLT reduction
with lower NAA concentrations is not a mere consequence of
global brain tissue loss as one could assume given the correlation of
RNFLT with BPF in both our work and that of others [13][15].
On the contrary, loss of NAA in the visual cortex appears to be
associated with thinning of the RNFL independently from brain
atrophy. These findings could indicate that – beyond an
Figure 2. Correlation of RNFLT with BPF and
1H-MRS parameters. a) Depicted is the average RNFLT, every symbol representing a single eye
examined together with the corresponding BPF values. The symbols represent the patient’s previous history of optic neuritis (open circles – no
previous optic neuritis, grey squares - unilateral optic neuritis, black triangles – bilateral optic neuritis) A linear correlation function was calculated by
a Generalised Linear Model to account for intra-individual inter-eye relationships (p=0.001). b) Mean BPF was calculated for three groups that were
defined based on their previous history of optic neuritis (white bar– no previous optic neuritis, grey bar - unilateral optic neuritis, black bar – bilateral
optic neuritis). The (-) symbol indicates a trend, but a missing significant correlation of group differences as calculated by ANOVA (p=0.055). Error
bars represent 26standard error of the mean (SEM). c) RNFLT averages are shown in relation to corresponding NAA concentrations in the visual
cortex (VC). The symbols are coded as in a). The correlation is significant (p=0.047). d) Mean visual cortex voxel (VC) NAA and the significance of
group differences was calculated for optic neuritis groups as in b). The asterisk indicates statistically significant (p=0.046) group differences. Error
bars represent 26 standard error of the mean (SEM). e) RNFLT averages are shown in relation to corresponding NAA concentrations in normal-
appearing white matter (NAWM). The symbols are coded as in a). No significant correlation was found (p=0.531). f) Mean NAA in normal-appearing
white matter (NAWM) and the significance of group differences was calculated for optic neuritis groups as in b) (p=0.429). Error bars represent 26
standard error of the mean (SEM).
doi:10.1371/journal.pone.0018019.g002
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detectable by measurement of global brain tissue loss and also by
RNFL measurements - additional progressive neurodegenerative
damage may evolve in specific tracts or functional systems such as
the visual pathway. This assumption is further supported by
previous studies describing visual pathway damage in MS by
means of voxel-based morphometry, diffusion tensor imaging or
magnetization transfer ratio[33–35], and damage to other
functional systems such as pathways involved in learning and
memory [36–37]. The connection between the anterior and
posterior visual pathway damage raises the question of a mutual
interdependency of these alterations and implicates the possible
existence of transsynaptic damage processes in the anatomical
correlates of the visual pathway in MS. This concept has already
been described recently for glaucoma[38–39] and in the context of
amblyopia[40] and in congenital or acquired homonymous
hemianopia [41]. In this regard, the lateral geniculate nucleus
(LGN) as region of change-over from axons deriving from the
anterior visual pathway to neurons from which axons forming the
optic radiation emerge is of importance. Interestingly, a histo-
pathological study of neuronal changes in the LGN by Evangelou
et al. [42] strongly supports the concept of transsynaptic
degeneration. In this context, Green et al. could show just recently
by a larger histopathological study, that retinal atrophy and
intraretinal inflammation may exceed previous assumptions,
indicating that also other structures of the foremost part of the
visual pathway, as the retinal inner nuclear layer, may be affected
by transsynaptical axonal and neuronal degeneration, not only the
retinal nerve fiber layer [43]. This hypothesis is further supported
by our findings of lower RNFL thickness in patients with previous
optic neuritis compared to those without, in line with earlier
reports[12][44–45], and concordantly also lower visual cortex
NAA concentrations in patients with previous optic neuritis.
However, the underlying pathophysiological mechanisms remain
to be elucidated, including the direction of damage cascades
(anterograde, retrograde) and their temporal evolution. These
mechanisms cannot be deduced from cross-sectional studies, as
these only provide a description of the current status within a
narrow time-frame.
A methodological limitation of our study is the lack of an
additional MRS voxel containing mixed or gray matter in another
brain region than the visual cortex. Preferably, a separate cortex
voxel representative for an independent functional pathway, such
as a voxel covering the motor cortex, could have been used as a
more appropriate control region, which could not be applied in
our study to limit scan time to an acceptable extent. The reduced
cortical NAA concentrations and RNFL thinning may not be
specific for the visual cortex but might also have been detected in
other cortex regions, thus only indicating a relationship between
two different parameters depicting global neurodegeneration.
However, despite this limitation we believe that our findings from
this exploratory study could support the hypothesis of tract specific
damage to the visual pathway in MS as (i) NAA only in the visual
cortex voxel comprising both gray and white matter but not NAA
in the normal-appearing white matter voxel correlated with
RNFLT, and (ii) our subgroup analysis showed that the extent of
NAA reduction in the visual cortex voxel is related to the history of
optic neuritis. Notwithstanding, future studies on visual pathway
damage in MS should include additional cortical MRS voxel if
possible. In addition, the advent of novel spectral-domain OCT
devices with an improved spatial resolution and a better retest-
reliability, that replace the current time-domain OCT devices in
the future, will also contribute to a more accurate description of
the pathology of visual pathway damage on a morphological level
[46–47].
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